Developing small molecule inhibitors of a novel pathway to treat melanoma and other cancers.
Active Portfolio Company
http://enbpharma.com/
Active Portfolio Company
http://enbpharma.com/
Location: United States, New York
Investors 2
| Date | Name | Website |
| - | BioAdvance | bioadvance... |
| - | AJI Capita... | ajicap.com |
Mentions in press and media 2
| Date | Title | Description |
| 04.11.2022 | ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy | ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / November 4, 2022 / ENB Therapeutics, Inc., a biotechnology company pioneering a new an... |
| 14.07.2022 | ENB Therapeutics to Present at SVB Securities Biopharma Private Company Connect on July 20-21, 2022 | NEW YORK, NY / ACCESSWIRE / July 14, 2022 / ENB Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor (ETBR) inhibitor, today announced that ... |